Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Biotech Leaders, Patient Advocates Highlight Cutting-Edge HIV/AIDS Therapies, Need For Next Generation Treatments
Leaders in biotechnology research and patient advocacy joined forces today at the 2009 BIO International Convention to discuss the latest breakthroughs in HIV/AIDS treatments. Following a keynote speech by Sir Elton John focused on the needs of the HIV/AIDS community, representatives of biotech companies previewed the next generation of treatments while patient advocates reiterated the need for new therapies, particularly for those who have developed resistance to existing medications. Researchers are developing new therapies that are more effective in treating HIV/AIDS, including an AIDS vaccine and new methods of delivery that hold the potential to increase patient compliance.

Prospect Therapeutics, Inc.'s GCS-100 Inhibited Blood Vessel Formation In A Variety Of Cancer Models
Joseph F. Finn, Jr., C.P.A. ("Finn"), announced today that there has been promising initial interest from pharma companies in the intellectual property of Prospect Therapeutics, Inc. ("Prospect").
News of the day
Patient Recall Rates May Be Decreased By Digital Mammography Plus Digital Breast Tomosynthesis
Nationally, about ten percent of women in the US are recalled for a second mammogram after an abnormality is detected on the first one - for most women this can be very stressful. However the use of digital breast tomosynthesis and full-field digital mammography combined may be associated with a substantial decrease in recall rate, according to a study performed at UPMC in Pittsburgh, PA. Some researchers believe that digital breast tomosynthesis depicts the breast tissue in a way which may allow radiologists to identify some tumors which could be missed with standard two-dimensional mammography.
Health Insurance

The Union To Offer 8 MDR-TB Courses This Year

The Union will offer 8 MDR-TB courses in 2009 as part of its commitment to addressing the global increase in multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. The next 5-day intensive course will be held in Beijing, China on 18-22 May 2009. The Comprehensive Course on Clinical Management of Drug-Resistant Tuberculosis is designed for senior-level programme and clinical staff and emphasises practical knowledge and skills in the management of the MDR-TB. The course coordinators are Dr Jose A Caminero and Dr Chiang Chen-Yuan. Instruction will be in English, with Chinese translation as required. Topics addressed through lecture, discussion and practical exercises will cover: -- Biological characteristics and condition of M. tuberculosis growth -- Basic concepts in drug resistance -- Global epidemiology of M. tuberculosis resistance -- Clinical manifestations of TB and drug-resistant TB -- Analysis of factors contributing to MDR- and XDR-TB -- Conventional laboratory procedures for diagnosis and treatment follow-up of TB - Clinical relevance -- Approach to the diagnosis of drug-resistant tuberculosis -- Framework for programmatic management of MDR-TB - Update of the MDR-TB Guidelines (Chinese version) -- Infection control -- Support of the drug susceptibility testing for management of drug-resistant TB -- Techniques for rapid diagnosis of drug-resistant TB -- Initial Treatment of TB -- principles -- Tuberculosis, MDR-/XDR-TB, and HIV -- Treatment of MDR-TB and XDR-TB -- principles -- Rational use of first- and second-line drugs in the MDR/XDR-TB treatment -- Adverse reactions to first- and second -line drugs -- Management of the MDR-TB in special situations: pregnancy, et al. -- Management of contacts of MDR-TB patients -- Generation of MDR/XDR-TB in NTP conditions -- Framework for effective MDR-TB control: The Green Light Committee -- Reasoning the best treatment options for a NTP -- Addressing the most controversial clinical issues reviewed in the course Dr Jose A Caminero has been a consultant for The Union since 1996. He develops and teaches many of The Union"s technical courses and serves on the Technical Review Panel of the Stop TB Partnership"s Green Light Committee. Dr Chiang Chen-Yuan is the Director of The Union"s Department of Lung Health. Dr Chiang is an MDR-TB clinician and researcher who has developed and coordinated several post-graduate courses in MDR-TB in addition to providing on-site technical assistance on MDR-TB in China. 2009 Union courses on Multidrug-resistant Tuberculosis International courses VII Spanish International Course on Clinical Management of Drug-Resistant Tuberculosis Dates: 20-24 July 2009 Location: Santo Domingo, Dominican Republic Language: Spanish Application deadline: 31 May 2009 Max. no. of participants: 30 II English International Course on Clinical Management of Drug-Resistant Tuberculosis Dates: September 21-25 2009 Location: Manila, The Philippines Language: English Application deadline: 30 June 2009 Max. no. of Participants: 30 I International Course for Portuguese-speaking countries Dates: November 2-6, 2009 Location: Rio de Janeiro, Brazil Attendance only by invitation of the Brazilian NTP National courses National Course of Mexico April 19-21 2009 This course has already finished. National Course of Namibia June 29 - July 1 2009 Attendance only by invitation of the Namibian NTP National Course of Dominican Republic July 20-22 2009 Attendance only by invitation of the Dominican Republic NTP National Course of China May 18-22 2009 Attendance only by invitation of the China NTP Post-graduate Courses Clinical and Programmatic Management of MDR- and XDR-TB Date: 9 September 2009 Location: Beijing, China This post-graduate course is presented in conjunction with the 2nd Conference of the Union Asia Pacific Region, 9-12 September 2009 in Beijing, China. The conference theme is "Prevention and Control of Multidrug-Resistant Tuberculosis." For more information, please visit The Union website. You may also write to mail@bjiualtd-apr.com International Union Against Tuberculosis and Lung Disease


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009